Solventum key statistics and ratios

In fiscal 2025, Solventum had return on equity of 38.9%, an operating margin of 26.2%, debt equal to 100.7% of equity and a current ratio of 1.23. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Solventum: financial ratios, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	57.7%	57.3%	55.6%	53.5%	54.7%
Operating margin	20.8%	20.6%	12.6%	26.2%	25.0%
Net margin	16.5%	16.4%	5.8%	18.7%	17.3%
Free-cash-flow margin	17.6%	19.8%	9.8%	−0.1%	−1.4%
Return on equity	11.4%	11.5%	6.6%	38.9%	29.1%
Return on assets	—	9.7%	3.4%	10.8%	10.1%
Asset turnover	—	0.59	0.58	0.58	0.58
Current ratio	—	1.46	1.20	1.23	1.02
Debt to equity	0.0%	0.0%	273.1%	100.7%	105.9%
Effective tax rate	20.6%	19.3%	21.0%	9.2%	15.4%
R&D as % of revenue	9.4%	9.2%	9.4%	8.9%	8.7%
SG&A as % of revenue	27.5%	28.0%	33.7%	37.0%	39.6%
Capital spending as % of revenue	3.1%	3.5%	4.6%	4.6%	3.9%
Free cash flow ÷ net income	106.3%	120.7%	168.1%	−0.6%	−8.2%

US$ thousands unless shown otherwise. Fiscal quarters.

Solventum: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	56.0%	53.9%	53.8%	54.4%	54.2%	51.4%	54.7%	58.2%
Operating margin	13.2%	6.6%	7.3%	9.9%	80.6%	6.2%	4.0%	8.2%
Net margin	5.9%	1.5%	6.6%	4.2%	60.4%	3.2%	0.6%	4.2%
Free-cash-flow margin	3.7%	4.4%	−3.9%	2.7%	−1.0%	1.6%	−13.6%	6.5%
Current ratio	1.16	1.20	1.19	1.22	1.50	1.23	1.07	1.02
Debt to equity	254.0%	270.7%	242.6%	214.4%	103.0%	99.7%	102.2%	105.8%
R&D as % of revenue	9.1%	9.6%	9.3%	8.7%	8.7%	8.8%	9.4%	8.1%
SG&A as % of revenue	33.7%	37.8%	37.1%	35.7%	37.2%	38.0%	41.2%	42.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 5 checks passed · June 30, 2026

What it owns · $14.2bn

Short-term assets $3.7bnLonger-term assets $10.5bn

What it owes, and who funded it · $14.2bn

Short-term liabilities $3.7bnLonger-term liabilities $5.8bnShareholders' equity $4.8bn

Short-term assets cover short-term liabilities $3.7bn of assets due within a year against $3.7bn of liabilities due within a year.
Short-term assets cover long-term liabilities $3.7bn short-term assets against $5.8bn of longer-dated liabilities.
More cash than debt $403m of cash against $5.1bn of debt.
Debt below 40% of shareholders' equity Debt is 106% of equity.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt $209m of operating cash flow against $5.1bn of debt.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Solventum's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: SOLV vs VEEV SOLV vs TDOC SOLV vs TEM

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Solventum's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Solventum.